Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines of Chemotherapy

NCT03123393 is registered in ClinicalTrials.gov with Calithera Biosciences, Inc as lead sponsor.

NCT NCT03123393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03123393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines of Chemotherapy
Lead sponsor
Calithera Biosciences, Inc
Phase
Phase 2
Overall status
Terminated
Start date
October 10, 2017
Completion date
December 17, 2019
Enrollment
49 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma